Drug Discovery World

DECEMBER 19, 2022

From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. Key takeaways: Use of native human IgE sequences as a foundation to develop optimal therapeutics. Benefits of scRNA-seq for understanding IgE and disease.

Antibody 52

Antibody Allergies Genome Genomics 52

Drug Discovery World

NOVEMBER 15, 2022

From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. Key takeaways: Use of native human IgE sequences as a foundation to develop optimal therapeutics. Benefits of scRNA-seq for understanding IgE and disease.

Antibody 52

Antibody Allergies Genome Genomics 52

Drug Discovery Today

FEBRUARY 16, 2021

Celltrion is on track developing a neutralising antibody cocktail with Regdanvimab (CT-P59) tailored to fight against the emerging new variants. CT-P59 demonstrated neutralising capability against key emerging mutations, including the UK variant in addition to six variant genome mutations of SARS-CoV-2.

Antibody 45

Antibody Development Genome Genomics 45

Drug Discovery World

NOVEMBER 16, 2022

Join DDW for this free event Harnessing the power of IgE antibodies to create novel therapeutics. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. It will take place on December 13, 2022 at 5PM GMT and will be supported by SPT Labtech.

Antibody 52

Antibody Allergies Genome Genomics 52

Drug Discovery World

APRIL 25, 2024

Reece Armstrong offers an overview of cell line development and outlines the benefits the technology is bringing to biopharmaceutical developers. Cell line development is an essential underpinning of the drug development process, enabling teams to test, optimise and manufacture therapeutics at a commercial scale.

Development 59

Development Protein In-Vivo Life Science 59

Drug Discovery World

DECEMBER 7, 2022

Biotechnology company Infinimmune has closed a $12 million seed round to focus on human-derived antibody drugs. The industry has proven the value of antibody-based drugs, but the limited number of both drugs and targets demonstrates a need for new approaches to discovery,” said Wyatt McDonnell, CEO and Co-founder of Infinimmune. . “The

Antibody 52

Antibody Drugs Genome Genomics 52

pharmaphorum

FEBRUARY 18, 2021

GlaxoSmithKline is expanding a coronavirus antibody collaboration with US biotech Vir, to include potential therapies for flu and other respiratory viruses. Several firms are already working on COVID-19 antibody therapies, with Regeneron and Eli Lilly leading the way and AstraZeneca also in the mix with a long-acting antibody.

Antibody 97

Antibody Development Genome Genomics 97

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Antibody 52

Antibody Licensing Licensing Development 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

XTalks

SEPTEMBER 30, 2020

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. These rogue antibodies blocked interferon action and were not present in patients with mild COVID-19 cases.

Antibody 135

Antibody Genetics Research In-Vitro 135

Drug Discovery World

MARCH 25, 2024

“The potential for CAR T as a therapeutic option for autoimmune disease has captured the collective imagination of the scientific community,” said Zachary Roberts, Executive Vice President of Research & Development and Chief Medical Officer of Allogene.

Gene Editing 52

Gene Editing Drugs Genome Genomics 52

The Pharma Data

NOVEMBER 26, 2020

26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings. CHICAGO , Nov.

DNA 52

DNA Antibody Research Genome 52

The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R.

Antibody 52

Antibody DNA Containment Manufacturing 52

XTalks

NOVEMBER 20, 2020

A new type of test based on detection of activated T cells may prove to have greater utility in determining whether someone has had a COVID-19 infection compared to a traditional antibody test. Researchers at Adaptive Biotechnologies compared T-Detect to a commercial antibody test from DiaSorin on samples obtained from people in Vo’, Italy.

Antibody 98

Antibody Immune Response Protein In-Vitro 98

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. These animals have been used as a key tool in functional genomics to generate models for human diseases and to validate new drugs.

Genetics 130

Genetics DNA Antibody Genome 130

Drug Discovery World

FEBRUARY 12, 2024

Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery. The emergence of low-code and no-code software engineering will start to make CGT application development easier, enabling more rapid, innovative solutions.

Genome 139

Genome Genomics Life Science Gene Therapy 139

The Pharma Data

DECEMBER 31, 2020

Antibodies Respond Differently to Severe Versus Mild COVID-19. Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. People with severe COVID-19 have low proportions of antibodies that target the spike protein.

Antibody 52

Antibody Research Bacteria Genetics 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

pharmaphorum

MARCH 24, 2022

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. Greg Verdine – LifeMine. Image by jggrz from Pixabay .

Medicine 102

Medicine Genome Genomics Engineer 102

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene 262

Gene Gene Therapy Genetics DNA 262

pharmaphorum

OCTOBER 4, 2022

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million. The LogicBio deal is the latest in a string of acquisitions for AstraZeneca.

Gene Editing 62

Gene Editing Gene Genome Genomics 62

The Pharma Data

DECEMBER 17, 2020

Farber extended congratulations to GSK on behalf of the alliance: “An effective treatment developed specifically for lupus nephritis has been desperately needed. We are particularly proud to see this approval for another indication of belimumab, having funded much of the original research that led to the drug’s development.

FDA Approval 52

FDA Approval Genome Genomics Production 52

Drug Discovery World

DECEMBER 21, 2023

DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. Read the article – Three trends in the antibody-drug conjugate (ADC) market Expert view: What’s next for cell and gene therapy?

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

Pharmaceutical Technology

DECEMBER 9, 2022

M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. Pharmaceutical Technology Excellence Rankings – The Verdict. Integrated analytical services for pharmaceuticals.

Development 130

Development Production Manufacturing Vaccination 130

Drug Discovery World

MAY 13, 2024

RA: How can rational design approaches help advance vaccine development? MA: Regarding vaccine development specifically, and the role my team plays in the development of cryogenic electron microscopy (cryo-EM) technology, we see the study and dissemination of virus structures, and the proteins that comprise them, as vital to vaccine design.

Vaccination 59

Vaccination Vaccine Protein Antibody 59

Drug Discovery World

NOVEMBER 27, 2023

Across the biotherapeutics workflow The landscape of large molecule drug development has evolved significantly in recent decades. Technological innovations supporting discovery and development stages have concentrated on both upstream and downstream aspects of the workflow.

Production 59

Production Engineer Gene Editing Gene 59

The Pharma Data

OCTOBER 9, 2021

Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S. Roche’s Chief Medical Officer and Head of Global Product Development. Source link: [link].

Antibody 52

Antibody In-Vitro Trials Development 52

Drug Discovery World

MARCH 27, 2023

Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Ono will have an exclusive option to license global rights to the candidates for further development and commercialisation.

Drugs 52

Drugs Antibody Genome Genomics 52

Drug Discovery World

MARCH 13, 2024

Thanks to significant investment by the government into research and development, Singapore has become a leading centre for biomedical sciences in Asia. Following this, a medical innovation and development centre, Biopolis Hub, was opened in 2005. UK-based molecular diagnostics group Yourgene operates in Singapore.

Life Science 69

Life Science Genome Genomics Research 69

Drug Discovery World

OCTOBER 5, 2023

Experts and thought leaders in cancer research, precision medicine and immunotherapy will describe the latest research and the role of technology to help discover targets, develop cancer therapeutics and vaccines and, get to market faster. What are the best research tools to aid development of new treatments and vaccines?

Research 52

Research Antibody Medicine RNA 52

Pharmaceutical Technology

JULY 5, 2022

The team also found that the oral compound, RG7834, developed by Hoffmann-La Roche, hindered replication at a crucial step, preventing the virus from infecting liver cells. HAV usually hijacks TENT4 and utilises it for the replication of its own genome.

Protein 130

Protein RNA Genome Genomics 130

Drug Discovery World

APRIL 8, 2024

Aviv Regev, Head and Executive Vice President of Research and Early Development at Genentech, opened the session with a discussion of how advances in genomic sequencing are fostering the development of data-rich cell atlases and what that data could mean for new insights into cancer biology and novel therapeutics.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

pharmaphorum

DECEMBER 5, 2022

The French biotech says VLA1553 met its objective in the phase 3 study, with 99% of patients exhibiting an antibody response against the virus 12 months after receiving a single dose of the shot, with no evidence of a tailing off in levels in the last six months. It will continue for up to five years.

Vaccination 98

Vaccination Vaccine Antibody Allergies 98

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?

RNA 64

RNA In-Vivo In-Vitro DNA 64

Pharmaceutical Technology

MARCH 9, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Antibody 130

Antibody Hormones DNA Genome 130

Drug Discovery World

MAY 29, 2024

SpyBiotech and the University of Oxford Biotechnology company SpyBiotech and University of Oxford have entered a research agreement for the development of a vaccine against Epstein-Barr virus (EBV). ERS Genomics and IRBM ERS Genomics and IRBM have signed an agreement granting IRBM access to ERS’ CRISPR/Cas9 patent portfolio.

Drugs 52

Drugs Gene Editing Life Science Genome 52